.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Dow
Moodys
Teva
Farmers Insurance
Federal Trade Commission
Cantor Fitzgerald
Express Scripts
Novartis
Argus Health

Generated: July 25, 2017

DrugPatentWatch Database Preview

DEXAIR Drug Profile

« Back to Dashboard

Which patents cover Dexair, and when can generic versions of Dexair launch?

Dexair is a drug marketed by Pharmafair and is included in two NDAs.

The generic ingredient in DEXAIR is dexamethasone sodium phosphate. There are thirty-nine drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the dexamethasone sodium phosphate profile page.

Summary for Tradename: DEXAIR

Patents:0
Applicants:1
NDAs:2
Bulk Api Vendors: see list66
Patent Applications: see list3,238
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DEXAIR at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmafair
DEXAIR
dexamethasone sodium phosphate
SOLUTION/DROPS;OPHTHALMIC088433-001Dec 15, 1983DISCNNoNo► Subscribe► Subscribe► Subscribe
Pharmafair
DEXAIR
dexamethasone sodium phosphate
OINTMENT;OPHTHALMIC088071-001Dec 28, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Queensland Health
Chinese Patent Office
Novartis
Teva
Daiichi Sankyo
Federal Trade Commission
Express Scripts
Moodys
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot